نتایج جستجو برای: proteasome inhibitor

تعداد نتایج: 224881  

2017
Tereza Nehybová Jan Šmarda Lukáš Daniel Marek Stiborek Viktor Kanický Ivan Spasojevič Jan Preisler Jiří Damborský Petr Beneš

Wedelolactone is a multi-target natural plant coumestan exhibiting cytotoxicity towards cancer cells. Although several molecular targets of wedelolactone have been recognized, the molecular mechanism of its cytotoxicity has not yet been elucidated. In this study, we show that wedelolactone acts as an inhibitor of chymotrypsin-like, trypsin-like, and caspase-like activities of proteasome in brea...

Journal: :Journal of virology 2009
P S Satheshkumar Luis C Anton Patrick Sanz Bernard Moss

The ubiquitin-proteasome system has a central role in the degradation of intracellular proteins and regulates a variety of functions. Viruses belonging to several different families utilize or modulate the system for their advantage. Here we showed that the proteasome inhibitors MG132 and epoxomicin blocked a postentry step in vaccinia virus (VACV) replication. When proteasome inhibitors were a...

2011
Carol H. Y. Wu Julie Y. H. Chan Samuel H. H. Chan Alice Y. W. Chang

BACKGROUND Brain stem cardiovascular regulatory dysfunction during brain death is underpinned by an upregulation of nitric oxide synthase II (NOS II) in rostral ventrolateral medulla (RVLM), the origin of a life-and-death signal detected from blood pressure of comatose patients that disappears before brain death ensues. Furthermore, the ubiquitin-proteasome system (UPS) may be involved in the s...

2015
David S. Pitcher Kate de Mattos-Shipley Konstantinos Tzortzis Holger W. Auner Anastasios Karadimitris Maurits F. Kleijnen

The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib - exhibiting a low-nanomolar IC(50) - suggesting that minimal inhibition of degradation suffices to kill MM cells. Instead, we report, a low Bortezomib concentration, contrary to expectatio...

Journal: :Journal of cell science 2010
Vian Azzu Martin D Brand

Mitochondrial uncoupling protein 2 (UCP2) is implicated in a wide range of pathophysiological processes, including immunity and diabetes mellitus, but its rapid degradation remains uncharacterized. Using pharmacological proteasome inhibitors, immunoprecipitation, dominant negative ubiquitin mutants, [corrected] cellular fractionation and siRNA techniques, we demonstrate the involvement of the u...

Journal: :Journal of cell science 2004
Edward Leithe Edgar Rivedal

Connexins are membrane-spanning proteins that form gap junction channels between adjacent cells. Connexin43 (Cx43), the most widely expressed member of the connexin family in tissues and cell lines, has a rapid turnover rate and its degradation involves both the lysosomal and ubiquitin-proteasome pathway. It was previously shown that the proteasome is involved in regulating the number of functi...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2009
Toyoko Hiroi Clayton B Deming Haige Zhao Baranda S Hansen Elisabeth K Arkenbout Thomas J Myers Michael A McDevitt Jeffrey J Rade

OBJECTIVE Impairment of the thrombomodulin-protein C anticoagulant pathway has been implicated in pathological thrombosis associated with malignancy. Patients who receive proteasome inhibitors as part of their chemotherapeutic regimen appear to be at decreased risk for thromboembolic events. We investigated the effects of proteasome inhibitors on endothelial thrombomodulin expression and functi...

Journal: :Plant & cell physiology 2002
Yuki Yanagawa Seiichiro Hasezawa Fumi Kumagai Masayoshi Oka Masahiro Fujimuro Tae Naito Taro Makino Hideyoshi Yokosawa Keiji Tanaka Atsushi Komamine Junji Hashimoto Takahide Sato Hiroki Nakagawa

The 26S proteasome is known to play pivotal roles in cell-cycle progression in various eukaryotic cells; however, little is known about its role in higher plants. Here we report that the subcellular distribution of the 26S proteasome is dynamically changed in a cell-cycle dependent manner in tobacco BY-2 cells as determined by immunostaining with anti-Rpn10 (a regulatory PA700 subunit) and anti...

Journal: :American Journal of Hematology 2021

The median overall survival in multiple myeloma is rapidly approaching 10 years; however, nearly a fifth of patients the prognosis remains poor. Therefore, modern-day management should be individualized, with more intense and continuous approach these high-risk patients. This includes first-line treatment based on multi-drug combinations employing most effective drug combinations, upfront autol...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید